Sulphonamide derivatives
CA 2278790 A1 · Owner: Mckennon, Tracey Elaine · Inventors: Arnold, Macklin Brian; Escribano, Ana Maria; Bleisch, Thomas John
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Glutamate receptor function in a mammal may be potentiated using an effective amount of a compound of formula (I): R1-L-NHSO2R2 in which R1 represents an , unsubstituted or substituted aromatic or heteroaromatic group; R2 represents (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)fluoroalkyl (1-6C)chloroalkyl, (2-, 6C)alkenyl, (1-4C)alkoxy(1-4C)alkyl phenyl which is unsubstituted or , substituted by halogen (1-4C)alkyl or (1-4C)alkoxy, or a group of formula , R3R4N in which R3 and R4 each independently represents (1-4C)alkyl or together with the nitrogen atom to which they are attached form an azetidinyl pyrrolidinyl, piperidinyl, morpholino, piperazinyl hexahydroazepinyl or , octahydroazocinyl …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 30, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 30, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 30, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.